Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease

Movement Disorders

Volumn 26, Issue 10, 2011, Pages 1875-1880

  Shanker, Vicki ^a   Groves, Mark ^a   Heiman, Gary ^b   Palmese, Christina ^a   Saunders Pullman, Rachel ^a   Ozelius, Laurie ^c   Raymond, Deborah ^a   Bressman, Susan ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cognition; Depression; Leucine rich repeat kinase 2; Mood; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ADULT; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; JEW; LETTER; MALE; MINI MENTAL STATE EXAMINATION; MOOD; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHIATRY; RISK FACTOR; SEMI STRUCTURED INTERVIEW; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; JEWS; MALE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; PSYCHIATRIC STATUS RATING SCALES; SERINE;

EID: 80052260605     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23746     Document Type: Letter

References (49)

1. Nussbaum R, Ellis C. Alzheimer's disease and Parkinson's disease. N Engl J Med. 2003; 348: 1356-1364.
2. Samii A, Nutt J, Ransom B. Parkinson's disease. Lancet. 2004; 363: 1783-1793.
3. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol. 2005; 18: 363-369.
4. Tan E, Skipper L. Pathogenic mutations in Parkinson disease. Hum Mutat. 2007; 28: 641-653.
5. Dick F, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med. 2007; 64: 666-672.
6. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord. 1996; 11: 17-23.
7. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand. 2002; 105: 77-82.
8. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 2002; 51: 296-301.
9. Paisán-Ruíz C, Jain S, Evans E, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004; 44: 595-600.
10. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18: R48-R59.
11. Simón-Sánchez J, Schulte C, Bras J, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009; 41: 1308-1312.
12. Ozelius L, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006; 354: 424-425.
13. Clark L, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006; 67: 1786-1791.
14. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007; 69: 1595-1602.
15. Adams J, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005; 128: 2777-2785.
16. Ross O, Toft M, Whittle A, et al. Lrrk2 and Lewy body disease. Ann Neurol. 2006; 59: 388-393.
17. Healy D, Falchi M, O'Sullivan S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008; 7: 583-590.
18. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord. 2006; 12: 410-419.
19. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol. 2005; 58: 784-787.
20. Nishioka K, Kefi M, Jasinska-Myga B, et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010; 81: 391-395.
21. Alcalay R, Mejia-Santana H, Tang M, et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009; 66: 1517-1522.
22. Pankratz N, Marder K, Halter C, et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord. 2008; 23: 2216-2223.
23. Lohmann E, Leclere L, De Anna F, et al. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. Parkinsonism Relat Disord. 2009; 15: 273-276.
24. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56: 33-39.
25. Folstein M, Folstein S, McHugh P, Fanjiang G. Mini-Mental State Examination User's Guide. Odessa, FL: Psychological Assessment Resources; 2001.
26. Benedict R, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998; 12: 43-55.
27. Brandt J, Benedict RHB. Hopkins Verbal Learning Test-Revised (HVLT-R). Odessa, FL: Psychological Assessment Resources; 2001.
28. Benton A, Siva A, Hamsher K, Varney N, Spreen O. Judgment of line orientation. In: Contributions to Neuropsychological Assessment: A Clinical Manual. 2nd ed. New York, NY: Oxford University Press; 1994: 53-64.
29. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000; 55: 1621-1626.
30. Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010; 133(pt 8): 2382-2393.
31. Beck A. Beck Anxiety Inventory. San Antonio, TX: Psychcorp Inc.; 1993.
32. Beck A, Steer R. Beck Depression Inventory-II. San Antonio, TX: Psychcorp Inc.; 1996.
33. Maher BS, Marazita ML, Zubenko WN, et al. Genetic segregation analysis of recurrent, early-onset major depression: evidence for single major locus transmission. Am J Med Genet. 2002; 114: 214-221.
34. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001; 57: 2089-2094.
35. Morrish P, Rakshi J, Bailey D, Sawle G, Brooks D. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998; 64: 314-319.
36. Fearnley J, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114: 2283-2301.
37. Gonera E, van't Hof M, Berger H, van Weel C, Horstink M. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 1997; 12: 871-876.
38. Braak H, Del Tredici K, Rüb U, de Vos R, Jansen Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
39. Schuurman A, van den Akker M, Ensinck K, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002; 58: 1501-1504.
40. Shiba M, Bower J, Maraganore D, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15: 669-677.
41. Arabia G, Grossardt B, Geda Y, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry. 2007; 64: 1385-1392.
42. Rocca W, Peterson B, McDonnell S, et al. The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics. Neuroepidemiology. 2005; 24: 151-167.
43. McKinlay A, Grace R, Dalrymple-Alford J, Roger D. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord. 2009; 28: 121-129.
44. McKinlay A, Grace R, Dalrymple-Alford J, Roger D. Characteristics of executive function impairment in Parkinson's disease patients without dementia. J Int Neuropsychol Soc. 2010; 16: 268-277.
45. Gill D, Freshman A, Blender J, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008; 23: 1043-1046.
46. Mamikonyan E, Moberg P, Siderowf A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord. 2009; 15: 226-231.
47. Nazem S, Siderowf A, Duda J, et al. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009; 57: 304-308.
48. Zadikoff C, Fox S, Tang-Wai D, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord. 2008; 23: 297-299.
49. Alcalay R, Mejia-Santana H, Tang M, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010: 1-5.